Anastrozole vs Thyroid (Levothyroxine / Liothyronine T3/T4)

Mechanism

Anastrozole is a potent, selective, non-steroidal third-generation aromatase inhibitor that competitively binds the heme group of cytochrome P450 aromatase (CYP19A1), blocking the conversion of testosterone to estradiol and androstenedione to estrone. In men on TRT, this reduces circulating estradiol by 50-80%, shifting the testosterone-to-estradiol ratio favorably. Estrogen suppression releases hypothalamic negative feedback, increasing GnRH, LH, and FSH secretion in non-TRT contexts. Complete estrogen ablation is detrimental to bone density, lipid metabolism, and cognitive function.

Standard Dosing

Research indicates 0.25-0.5 mg twice weekly as a TRT adjunct for estrogen management. Stand-alone hypogonadism: 1 mg twice weekly.

Timing

Take on testosterone injection days or the day after when aromatization peaks. Consistent schedule for stable estradiol control.

Cycle Duration

Ongoing as needed alongside TRT. Reassess every 3-6 months with estradiol labs. Goal is minimal effective dose.

Side Effects

• Joint pain and stiffness (from excessive estrogen suppression)
• Bone density loss with chronic use
• Lipid profile worsening (HDL suppression)
• Fatigue and brain fog (from over-suppression of estradiol)
• Mood disturbances and depression
• Hot flashes
• Decreased libido (if estradiol drops below ~15 pg/mL)

Contraindications

• Premenopausal women
• Known hypersensitivity to anastrozole
• Pre-existing severe osteoporosis (estrogen suppression worsens bone loss)
• Children (may affect bone growth plate closure)

Best Stacking Partners

Mechanism

Levothyroxine (T4) is a prohormone converted to the active triiodothyronine (T3) by type 1 and type 2 deiodinase enzymes (DIO1/DIO2) in peripheral tissues. T3 binds nuclear thyroid hormone receptors (TRa and TRb), forming heterodimers with retinoid X receptors (RXR) that bind thyroid response elements (TREs) in DNA, directly modulating transcription of genes controlling basal metabolic rate, thermogenesis, mitochondrial biogenesis (via PGC-1a), cardiac output, and neuronal development. T3 also exerts rapid non-genomic effects on mitochondrial respiration, ion channels, and cell membrane transport.

Standard Dosing

Research indicates Levothyroxine (T4): 25-200 mcg daily based on TSH and free T4 levels. Liothyronine (T3): 5-25 mcg daily, often split into 2-3 doses. Combination T4/T3 ratio typically 4:1 to 3:1 when using both.

Timing

Levothyroxine: Take on empty stomach, 30-60 minutes before breakfast or at bedtime (3+ hours after last meal). Separate from calcium, iron, and antacids by 4 hours. Liothyronine: Split into 2-3 daily doses due to short half-life (2.5 hours for T3 vs. 6-7 days for T4).

Cycle Duration

Ongoing for diagnosed hypothyroidism. Optimization protocols may be shorter-term (3-6 months) with reassessment.

Side Effects

• Tachycardia and palpitations (overdose or too-rapid titration)
• Anxiety and insomnia (particularly with T3)
• Tremor
• Weight loss (excessive dosing)
• Hair loss (temporary during initiation or dose changes)
• Heat intolerance and sweating
• Bone density loss at suppressive doses (TSH <0.1)

Contraindications

• Untreated adrenal insufficiency (correct cortisol before thyroid replacement)
• Acute myocardial infarction
• Thyrotoxicosis
• Known hypersensitivity to levothyroxine or liothyronine

Best Stacking Partners